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Background:Mutation epidemiology in each ethnic group is a crucial step of strategies for cystic fibrosis (CF) diagnosis and counselling. To date,
the scanning of the whole coding region of the cystic fibrosis transmembrane conductance regulator (CFTR) gene permits to identify about 90% of
alleles from patients bearing CF and a lower percentage in patients bearing atypical CF. CFTR rearrangements in heterozygosis elude current
techniques for molecular analysis, and some of them have been reported with a frequency up to 6% in various ethnic groups.
Methods: Using quantitative PCR analysis of all coding regions, we assessed the occurrence of CFTR rearrangements in 130 alleles from classic
CF patients and in 198 alleles from atypical CF patients (all unrelated and from Italian descent) bearing unidentified mutations after the scanning
of CFTR.
Results: Seven rearrangements (i.e., dele1, dele2, dele2_3, dele 14b_17b, dele17a_18, dele22_23, and dele22_24) were identified in 34/131
(26.0%) CF alleles bearing undetected mutations (which means about 2.5% of all CF alleles) and in none of the 198 alleles from atypical CF. The
CFTR haplotype and the sequence analysis of the breakpoints confirmed the common origin of all the rearrangements. Thus, we set up a novel
duplex PCR assay for the large-scale analysis of the seven rearrangements. The procedure was rapid (all PCR amplifications were obtained under
the same conditions), costless and repeatable.
Conclusions: It is useful to select the CFTR rearrangements more frequent in specific ethnic groups and to set up procedures for large-scale
analysis. Their study can be performed in cases in which a high detection rate is required (i.e., partners of CF carriers/patients). On the contrary,
the analysis of rearrangement is useless in atypical CF patients.
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Cystic fibrosis (CF) is the most frequent severe autoso-
mal recessive disorder in Caucasian populations, with a fre-⁎ Corresponding Author. CEINGE-Biotecnologie Avanzate scarl, Via Comu-
nale Margherita n. 482, 80145 Naples, Italy, Tel.: +39 0813737859; fax: +39
0813737859.
E-mail address: castaldo@dbbm.unina.it (G. Castaldo).
1569-1993/$ - see front matter © 2007 European Cystic Fibrosis Society. Publishe
doi:10.1016/j.jcf.2007.12.004quency of about 1:2500 live births. Thus far, more than 1600
CF-causing mutations have been identified in the cystic
fibrosis transmembrane conductance regulator (CFTR) dis-
ease-gene [1]. Mutation epidemiology in each ethnic group
is a crucial component of strategies for CF diagnosis and
counselling, because it permits to select the panel of mu-
tations with the highest detection rate to be routinely tested,
and to calculate the residual risk of being a CF carrier. To
date, the scanning of the whole coding region of the gened by Elsevier B.V. All rights reserved.
Table 1
Number and (percentage) of CF alleles bearing CFTR rearrangements
CF patients (n) CF alleles bearing
undetected mutations
Alleles bearing CFTR
rearrangements
Southern Italy (55) 62 19
Central Italy (30) 32 8
North-eastern Italy (36) 37 7
Total (121) 131 34
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90% of CF alleles [2–4].
More recently, atypical CF has been described, expressing
with a mild, monosymptomatic phenotype and usually asso-
ciated to normal sweat chloride and to a benign prognosis.
These forms include congenital bilateral absence of vasa de-
ferentes (CBAVD), recurrent pancreatitis, bronchiectasis and
others [5,6]. The detection rate of molecular analysis in these
forms is lower as compared to classical CF [7].
Large rearrangements of the CFTR gene may be identified
fortuitously either by noting a uniparental inheritance pattern, or
through failure to amplify target sequences if such mutations are
present in homozygosis. In fact, these mutations in heterozygosis
elude current techniques for molecular analysis, including
scanning procedures. Southern blotting, traditionally used for
detecting large genomic rearrangements, is rather laborious and,
therefore, scarcely useful for large-scale analysis. A macrodele-
tion involving CFTR exons 17a_18 has a high incidence among
Palestinian Arabs [8] and another involving CFTR exons 2_3
spreads in different ethnic groups [9]. The development of a rapid
technique of comparative dosage analysis permits to found such
gene rearrangements and a number of these mutations has been
identified in the French CF population [10]; thus, reports on large
gene deletions also in Italian patients appeared [11,12]. These
studies refer to patients bearing CF, while rearrangements in
patient bearing atypical CF are more rare [13–15].
The aim of our study was to define the incidence of CFTR
gene rearrangements in a large number of alleles from unrelated
Italian patients bearing CF or atypical CF, and to set up a novel
procedure for large-scale analysis.
2. Materials and methods
2.1. Patients
We studied 121 unrelated patients bearing CF selected from
three geographical areas: Southern (i.e., Campania and Basi-Table 2
CFTR haplotype associated to each rearrangement
CFTR rearrangement CF alleles XV2c KM19
Dele1 c.4_53+69del; 53+4192_53+4489inv; insG 2 (2, 0, 0) 1/2 1/2
Dele2 c.54-5811_164+2186del;273+6780_237+6961inv 8 (1, 2, 5) 1/2 1
Dele2_3 c.54-5490_273+10250del 1 (0, 1, 0) N.T. N.T.
Dele14b_17b c.2620-674_3367+198del 2 (0, 0, 2) 2 1
Dele17a_18 c.2988+1173_3468+2111del 14 (3, 3, 8) 2 2
Dele22_23 c.3964-78_4242+577del 2 (0, 1, 1) 2 2
Dele22_24 c.3964-3890_⁎3143delinsTAACT 5 (1, 1, 3) 2 1
N.T.: not tested. The numbers of CF alleles in parenthesis refer to North-eastern, Celicata regions, 55 cases); Central (i.e., Lazio and Molise regions:
30 cases); North-eastern Italy (Veneto region: 36 cases). All
patients had a classic form of the disease (i.e., altered sweat test,
pancreatic insufficiency and a different degree of respiratory
involvement), and were regularly in follow-up to the region-
al Centre for CF of each region. These patients had been selected
among all patients followed to these Centres because after
scanning analysis of the whole coding regions of CFTR, one
(111 patients) or both (10 patients) mutations resulted unde-
tected. Globally, 131 alleles had CFTR undetected mutations.
Furthermore, we studied 144 patients bearing atypical CF
forms, i.e., 84 congenital bilateral absence of vas deferens
(CBAVD); 26 recurrent pancreatitis; and 34 bronchiectasis.
Also these patients had been selected among all patients bearing
atypical CF from our Centre because after scanning analysis of
the whole coding regions of CFTR, one (90 patients) or both (54
patients) mutations resulted undetected. Globally, 198 alleles
had undetected mutations.
2.2. Methods
A sample of DNA from the above mentioned patients,
collected at the time of diagnostic molecular analysis, was used
for our study once received the informed consent from the
patient (or tutor for minors). In 85 CF patients and in all 144
patients bearing atypical CF, the analysis of CFTR rearrange-
ments was performed using a quantitative PCR followed by
capillary electrophoresis (MLPA SALSA, MRC-Holland, The
Netherlands). Deletions of probe recognition sequences appear
as a 35–50% reduced relative peak area of the amplification
product of that probe. Copy number of target sequences is
determined by a comparison to control samples. For each run,
three control samples were used, i.e., sample from a hetero-
zygote subject for a CFTR rearrangement, a wild-type sample
and a negative control (no DNA). Each rearrangement was
confirmed by gene sequencing analysis of the junction (protocol
available on request) with an automated procedure (3100
Genetic Analyzer, Applied Biosystem). The analysis of CFTR
intragenic STR IVS8CA, IVS17bTA and IVS17bCA was
performed by PCR followed by capillary electrophoresis set
up on 3130 Genetic Analyzer (Applied Biosystem) (protocol
available on request); the IVS8 TG repeat and diallelic
polymorphisms XV2c, KM19, J44 and M470V were analyzed
by direct gene sequencing.
The remaining 36 CF patients were analyzed using a
quantitative multiplex PCR amplification of short fluorescentJ44 IVS8 TG IVS8 CA M470V T854 IVS17b CA IVS17b TA
N.T. 7 16 2 1 13 30
2 7 16 2 1 13 30
N.T. N.T. N.T. N.T. N.T. N.T. N.T.
2 7 17 2 1 13 Partially deleted
1 9 23 1 1 Deleted Deleted
1 9 23 1 1 12 30
2 7 16 2 1 12 30
ntral and Southern Italy, respectively.
Fig. 1. Duplex PCR assay of the seven rearrangements. A) Gel electrophoresis
and B) schematic representation of the pattern in seven different heterozygous
patients bearing: 1) dele_1; 2) dele_2; 3) dele2_3; 4) dele14b_17b;
5) dele17a_18; 6) dele22_23; 7) dele22_24 and s.m) 100 bp size marker.
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semiquantitative-PCR: oligonucleotide primer pairs for ampli-
fying short fragments corresponding to the 27 exons of the
CFTR gene were used to construct six multiplex PCRs. Each
multiplex PCR assay also contained a control primer pair that
amplified a short exonic sequence of the hemocromatosis gene
(HFE). One primer of each pair was 5' labelled with the 6-FAM
fluorochrome. Amplified DNA fragments were separated on an
ABI PRISM 3130 (Applied Biosystem). The presence of aTable 3
Primers pairs for duplex PCR analysis of CFTR rearrangements
CFTR
rearrangement
Control
Exon Primers pair Amplicon s
Dele1 1 F: GGCAGGCACCCAGAGTAGTA 229
R: GCTTATTCCTTTACCCCAAACC
Dele2 2 F: TTCCATATGCCAGAAAAGTTGA 328
R: GCCACCATACTTGGCTCCTA
Dele2_3 2 F: TTCCATATGCCAGAAAAGTTGA 328
R: GCCACCATACTTGGCTCCTA
Dele14b_17b 17a F: ATGTGAAAATGTTTACTCACCAACA 466
R: ATGAATGTCCTGTACACCAACTGT
Dele17a_18 17a F: ATGTGAAAATGTTTACTCACCAACA 466
R: ATGAATGTCCTGTACACCAACTGT
Dele22_23 23 F: CCCATGGTTGAAAAGCTGAT 360
R: GCAATTTGCAGGAACTATCACA
Dele22_24 23 F: CCCATGGTTGAAAAGCTGAT 360
R: GCAATTTGCAGGAACTATCACA
⁎Amplicon involves the polymorphic (AT)n repeats.rearrangement is indicated by a two-fold reduction in the height
of the corresponding peak.
For the CFTR rearrangements we used the nomenclature by
Human Genome Variation Society, but within the text and in
tables, for each rearrangements we used a simplified nomen-
clature as follows: exon 1 rearrangement- c.4_53+69del53+
4192_53+4489invinsG alias dele1; exon 2 rearrangement-
c.54-5811_164+2186del273+6780_237+6961inv alias dele2;
exons 2 and 3 deletion- c.54-5490_273+10250del alias
dele2_3; exons 14b, 15, 16, 17a and 17b deletions- c.2620-
674_3367+198del alias dele14b_17b; exons 17a, 17b and 18
deletion- c.2988+1173_3468+2111del alias dele17a_18; exons
22 and 23 deletion- c.3964-78_4242+577del; exons 22, 23 and
24 rearrangement- c.3964-3890_⁎3143delinsTAACT alias
dele22_24. References [10] and [12] report diagrams showing
the proposed mechanisms of dele1 and dele2 mutations.
3. Results
As shown in Table 1, we identified a CFTR gene rear-
rangements in 34/131 (26.0%) CF alleles bearing undetected
mutations (which means about 2.5% of all CF alleles); the
occurrence of these mutations ranged between 18.9% (North-
eastern Italy) to 30.6% (Southern Italy). Table 2 shows the
distribution of these rearrangements in CF alleles from patients
of different origin (i.e., North-eastern, Central and Southern
Italy). Seven different gene rearrangements all previously
described were identified in these 34 alleles (Table 2). One
rearrangement (dele2_3) was observed in a single CF allele;
three of them (i.e., dele1, dele14b_17b, dele22_23) were
identified each in 2 CF alleles; the dele22_24 was identified in 5
CF alleles; the dele2 was identified in 8 CF alleles and finally,
dele17a_18 was identified in 14 CF alleles.
The analysis of extragenic (i.e., XV2c, KM19, J44) and
intragenic CFTR polymorphisms associated to each allele bear-
ing a rearrangement revealed that each of the six rearrangements
identified in more than a single allele is associated to a single
haplotype (Table 2). Sequence analysis confirmed that each ofDeletion
ize (bp) Primers pair Amplicon size (bp)
F: GGCAGGCACCCAGAGTAGTA 409
R: GCTTATTCCTTTACCCCAAACC
F: GGAATCAGAGGAGGGGAAAT 244
R: ATCATTCCCTCAGCATCCAA
F: ATTGACCACTTTAATGGTGTTTACCTA 200
R: TACACTCAGAACCCATCATAGGATAC
F: AATGTTTCCACCTTGAGAAAGC 338⁎
R: AATCTGTGTGCATCGGTTTTTA
F: CCCAAGTGAACTTTGGCATT 217
R: GCATGGGTGACAGCACTATG
F: CTGATTCTTTTGAGCTGTCAAGG 249
R: CAGAACTTCCTTGTGACTAAACCAT
F: TAAAGGATTCTGCTGCCACA 204
R: GGGGAGATATGTGGCCTTCT
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(data not shown).
The analysis of the 198 alleles bearing undetected CF mu-
tations from the patients with atypical CF revealed that none of
them had gene rearrangements.
To analyze the seven rearrangements on large-scale, we
developed a novel duplex PCR assay. We designed primers
flanking the deletion breakpoint that amplify a product of about
200 bp in the presence of the rearrangement, whereas control
primers generate a product of about 400 bp containing an intact
CFTR exon involved in the rearrangement. The only exception
is the deletion of exon 1. In this case the deletion spans 119 bp
and there is an insertion of 229 bp, so only one pair of primers is
required to obtain a 229 bp wild type PCR product and a 409 bp
mutated product. A standard PCR protocol was followed with
primer annealing set at 55 °C (data available on request). PCR
products were separated by 1% agarose gel electrophoresis and
visualized by ethidium-bromide staining (see an example in
Fig. 1A). All primers and product size are summarized in Table
3 and in Fig. 1B and also report the size of the fragments
obtained from the wild-type and the mutated allele for each
rearrangement. The same primers may be used also to detect the
junction by direct gene sequencing.
Using the novel procedure, we analyzed in blind all DNA
samples bearing rearrangements and an equivalent number of
controls. The analysis was performed in double, by two inde-
pendent operators, and provided the expected results, i.e., all
alleles were correctly classified.
4. Discussion
We observed a CFTR rearrangement in 26.0% of alleles from
Italian patients bearing CF with unidentified CFTR mutations
after gene scanning. Considering that the percentage of CF
alleles bearing undetected mutations after gene scanning anal-
ysis is 8 to 12% in different Italian regions [2–4], it means
that about 2.5% of alleles from Italian CF patients bear a
rearrangement.
Only seven CFTR rearrangements were been observed, i.e.,
dele1, dele2, dele2_3, dele14b_17b, dele17a_18, dele22_23
and dele22_24, and all these mutations had been previously
described in other populations. For example, the dele17a_18,
that we observed in 14 CF alleles, had been observed with a
high frequency also in Palestinian Arabs due to a founder effect
[8]. On the contrary, the dele2_3, observed only in 1 CF alleles
in our study had been described with a frequency ranging from
0 to 6% in CF alleles from a large series of ethnic populations
from Central and East Europe [9]. Furthermore, we identified 8
patients bearing the new insertion/deletion (dele2) recently
reported in 3.4% of CF alleles from Sardinian patients [12].
Even if the number of studied alleles is low, some differences
may exist in the distribution of the seven rearrangements in CF
alleles from patients of different origin (i.e., North-eastern,
Central and Southern Italy), as it has been previously described
for other CFTR mutations [4,16].
Each rearrangement observed in more than a single allele
in our study is associated to the same haplotype of CFTRpolymorphisms and this evidence, together to the observation
that the breakpoints coincide for all CF alleles bearing each of
the six rearrangements, confirms that each of these mutations
has a single origin. For the dele17a_18, the haplotype observed
in our population coincide with that reported for the same
mutation in Palestinian Arabs [8] with the exception of the
IVS8, that in our population is 23 and in the other is 22 due to a
slippage event or to a technical mis-typing; this observation, and
the concordance of the breakpoint suggests a common origin of
the mutation, even if it is difficult to speculate on a founder
effect both among Palestinian Arabs and Italians.
In any case, the coincidence of the breakpoint of all al-
leles bearing the same rearrangement, and the absence of other,
novel/rare macrodeletions in our population, suggest that the
seven rearrangements identified in our patients may be routinely
tested with the PCR of the junction avoiding PCR quantitative
procedures of the whole gene. It can be used a first level
approach, as those described in the present paper (duplex anal-
ysis), which is rapid, repeatable and costless, being based on
PCR amplification of all involved traits under the same con-
ditions. Otherwise, the direct gene sequencing can be performed
by labs that scan the whole CFTR gene.
From the diagnostic point of view, the analysis of rear-
rangements increases of about 2.5% the detection rate of mo-
lecular analysis, at least in our population, thus, it must be
performed in all cases in which a high detection rate is required
i.e., the partner of a CF carrier/patient, in which a more accurate
estimation of the risk is required.
Finally, in patients bearing atypical CF no rearrangements
were evidenced in the present study, confirming that these
mutations are rare among atypical CF alleles. Infact, Hantash et
al. described a single CBAVD bearing the deletion of exons 22
to 24 and 5T allele [13] and Taulan et al. detected two
heterozygous deletion, one encompassing exon 2 and the other
removing exons 22 to 24 in two males carrying a typical
CBAVD mutation on the other allele [15]. Thus, a strategy can
be to test for CFTR rearrangements only in atypical patients that
do not bear a “severe” CFTR mutations after first level analysis.
To conclude: seven CFTR rearrangements have a frequency
of about 2–3% in alleles from patients bearing CF in Italian
regions. The common origin of these mutations permits their
large-scale analysis with rapid and simple procedures as that
described in the present study. No rearrangements were iden-
tified in alleles from patients bearing atypical CF.
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